Enanta Pharmaceuticals, Inc. (ENTA)
11.10
-0.37
(-3.23%)
USD |
NASDAQ |
Oct 16, 16:00
11.12
+0.02
(+0.18%)
After-Hours: 20:00
Enanta Pharmaceuticals Research and Development Expense (Annual) : 106.74M for Sept. 30, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2025 | 106.74M |
| September 30, 2024 | 131.48M |
| September 30, 2023 | 163.52M |
| September 30, 2022 | 164.52M |
| September 30, 2021 | 174.11M |
| September 30, 2020 | 136.76M |
| September 30, 2019 | 142.21M |
| September 30, 2018 | 94.86M |
| Date | Value |
|---|---|
| September 30, 2017 | 57.45M |
| September 30, 2016 | 40.46M |
| September 30, 2015 | 23.19M |
| September 30, 2014 | 18.74M |
| September 30, 2013 | 16.84M |
| September 30, 2012 | 15.12M |
| September 30, 2011 | 11.55M |
| September 30, 2010 | 9.716M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics, Inc. | 70.96M |
| Coherus Oncology, Inc. | 104.96M |
| BridgeBio Pharma, Inc. | 451.95M |
| RenovoRx, Inc. | 6.269M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |